Genmab's $8 Billion Move: Acquiring Merus to Lead the Next Wave of Cancer Antibody Therapeutics

Denmark's Genmab is acquiring Dutch drugmaker Merus for $8 billion to secure petosemtamab, a late-stage, breakthrough treatment for head and neck cancer, bolstering Genmab's proprietary oncology pipeline and accelerating its evolution into a global biotechnology leader.